Latest Peripheral Nerve Repair News

Page 1 of 2
Orthocell Ltd reports steady progress in commercialising its nerve repair product Remplir in the US, with sales growth, expanded distributor networks, and manufacturing upgrades underpinning its path to profitability.
Ada Torres
Ada Torres
2 Feb 2026
ReNerve Limited reported a robust 80% increase in quarterly sales driven by strong US market adoption and expanded hospital approvals. The company advances its nerve repair product pipeline with key regulatory milestones and a refreshed board.
Ada Torres
Ada Torres
30 Jan 2026
ReNerve Limited has secured market approval for its NervAlign® Nerve Cuff in Malaysia, marking a key milestone in its Asia-Pacific expansion strategy. This approval follows earlier clearances in Hong Kong and Thailand, positioning the company to tap into a growing regional nerve repair market.
Ada Torres
Ada Torres
15 Jan 2026
ReNerve Limited has secured broader regulatory approval in Hong Kong for its NervAlign® Nerve Cuff, enabling access to both public and private hospitals and validating the device’s clinical benefits through independent review.
Ada Torres
Ada Torres
12 Jan 2026
Orthocell has lodged a regulatory application to distribute its nerve repair product Remplir™ across the EU and UK, aiming to tap into a $750 million market with approval expected by Q3 2026.
Ada Torres
Ada Torres
15 Dec 2025
Orthocell has achieved its first commercial sales of Remplir™ in Hong Kong, marking a pivotal step in its Asian growth strategy and expanding its footprint across key global markets.
Ada Torres
Ada Torres
10 Dec 2025
ReNerve Limited has raised $3.2 million through a two-tranche share placement to accelerate its sales and marketing efforts in the US and support upcoming product launches, including a new nerve conduit range.
Ada Torres
Ada Torres
20 Nov 2025
Orthocell Limited reports growing adoption of its Remplir™ nerve repair product in nerve-sparing prostate cancer surgeries across Australia, positioning for a significant U.S. market expansion. The company is investing in research and commercial infrastructure ahead of a medium-term U.S. launch.
Ada Torres
Ada Torres
20 Nov 2025
ReNerve Limited’s innovative NervAlign® Nerve Cuff has secured approval for use across the US Department of Defense and Veterans Affairs healthcare systems, marking a major milestone for the Australian medtech company.
Ada Torres
Ada Torres
13 Nov 2025
ReNerve Limited is scaling up its clinical trial for the NervAlign® Nerve Cuff following promising interim results that show significant pain reduction in nerve repair patients. The expanded study aims to solidify evidence for broader regulatory approval and market adoption.
Ada Torres
Ada Torres
5 Nov 2025
Orthocell has appointed a second Canadian distributor for its nerve repair device Remplir™, achieving full national coverage and setting the stage for initial sales this quarter.
Ada Torres
Ada Torres
5 Nov 2025
Orthocell has appointed MontsMed as the exclusive distributor for its nerve repair product Remplir™ in Hong Kong, marking a significant step in its Asian commercialisation strategy. This move opens access to the vast Guangdong-Hong Kong-Macao Greater Bay Area, complementing existing operations in Singapore and planned expansion in Thailand.
Ada Torres
Ada Torres
29 Oct 2025